AbbVie
MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion
MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion
AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion
AbbVie, Medincell, Long-acting injectable platform, Biotechnology, Deal, $1.9 billion
AbbVie Acquires Landos Biopharma to Enhance Post-Humira Immunology Pipeline
AbbVie, Landos Biopharma, Small acquisition, IBD (Inflammatory Bowel Disease) drug, Humira, Autoimmune startup, Immunology pipeline
MacroGenics and AbbVie Discontinue Development of ADAM9 Antibody-Drug Conjugate (IMGC936)
MacroGenics, AbbVie, Partnered ADC, ADAM9, IMGC936, Early Data, Safety Concerns, Efficacy Issues
AbbVie pours $223M into building out its biologics capacity in Singapore
Biological Factors, expansion, AbbVie, Capacity, Investments, Manufacture, Singapore